Ētahi atu korero ― Maori

Ko Squamous cell carcinoma (SCC) te tuarua o te mate pukupuku kiri e tino kitea ana i Amerika, i muri i te basal cell carcinoma. I te nuinga o te wa ka timata mai i nga mate mate pukupuku e kiia nei ko actinic keratosis , ka horapa atu ki etahi atu wahanga o te tinana. Ko te take nui ko te rongo ki te hihi ultraviolet (UV) mai i te ra, ka whakaemi i te waa. Ko te tikanga ko te tango i nga mahi tango, ina koa mo te SCC i runga i te mahunga me te kaki. Ko te rongoa iraruke he whiringa mo nga turoro pakeke, mo te hunga kaore e taea te mahi pokanga. Ka nui ake te mate o te SCC. Ahakoa onge, ka horapa te SCC, ina koa ki nga turoro kua ngoikore te punaha mate. He mea nui te arowhai me te whakamarumaru i te ra mo te hunga whai SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.

Ko Cutaneous squamous cell carcinoma (CSCC) te tuarua o nga mate pukupuku e tino kitea ana i roto i nga tangata, a kei te piki haere ona nama. Ahakoa te nuinga o te wa e whakaatu ana te CSCC i te whanonga haumanu pai, ka horapa ki te rohe me etahi atu wahanga o te tinana. Kua tautuhia e nga kaiputaiao nga huarahi motuhake e whai waahi ana ki te whanaketanga CSCC, e arai ana ki nga maimoatanga hou. Ko te nui o nga huringa me te nui ake o te tupono ki nga turoro immunosuppressed kua puta te whanaketanga o te immunotherapy. Ka titiro tenei arotake ki nga pakiaka ira o te CSCC me nga maimoatanga hou e aro ana ki nga ngota ngota motuhake me te punaha mate.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors